|
rs9380516
|
|
Hepatitis C
|
T |
0.700 |
GeneticVariation
|
GWASCAT |
Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection.
|
22841784 |
2012 |
|
rs76810409
|
|
Hepatitis C
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs76755915
|
|
Hepatitis C
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs75707332
|
|
Hepatitis C
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs7332270
|
|
Hepatitis C
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs7262634
|
|
Hepatitis C
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor.
|
24503447 |
2014 |
|
rs59888390
|
|
Hepatitis C
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs2978048
|
|
Hepatitis C
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor.
|
24503447 |
2014 |
|
rs2856723
|
|
Hepatitis C
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Human leukocyte antigen variants and risk of hepatocellular carcinoma modified by hepatitis C virus genotypes: A genome-wide association study.
|
28921602 |
2018 |
|
rs2647051
|
|
Hepatitis C
|
C |
0.700 |
GeneticVariation
|
GWASCAT |
Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.
|
30593799 |
2019 |
|
rs2647006
|
|
Hepatitis C
|
C |
0.700 |
GeneticVariation
|
GWASCAT |
Multi-Ancestry Genome-Wide Association Study of Spontaneous Clearance of Hepatitis C Virus.
|
30593799 |
2019 |
|
rs2492965
|
|
Hepatitis C
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs116399066
|
|
Hepatitis C
|
|
0.700 |
GeneticVariation
|
GWASCAT |
Impact of IFNL4 Genetic Variants on Sustained Virologic Response and Viremia in Hepatitis C Virus Genotype 3 Patients.
|
31260374 |
2019 |
|
rs8099917
|
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Among 1369 Urban Health Study participants, we evaluated genetic models for the association of IL28B genotype (rs12979860 and rs8099917) with hepatitis C virus (HCV) clearance.
|
22013224 |
2011 |
|
rs8099917
|
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found that the HCV genotype 1 responder genotypes at rs12979860 and rs8099917 did not associate with sustained virological response to PEG-IFN/ribavirin therapy.
|
21374656 |
2011 |
|
rs8099917
|
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Then, the impact of the IFNL3 single nucleotide polymorphism genotype (TT/non-TT at rs8099917) on treatment outcomes was evaluated in the 180 patients, and between patients infected with either HCV sub-genotype 2a or 2b.
|
25852275 |
2015 |
|
rs8099917
|
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, higher glucose levels were found in T2D patients carrying the IL28B CT/TT rs12979860 and GT/GG rs8099917 HCV risk genotypes compared to those with the protective CC and TT genotype (p=0.06 and p=0.02, respectively).
|
27664841 |
2016 |
|
rs8099917
|
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two single nucleotide polymorphisms were genotyped in the IL28B locus (rs12979860 and rs8099917) from 817 patients with chronic HCV infection, and substitutions at amino acids 70 and 91 of the HCV core protein and within the NS5A interferon sensitivity-determining region (ISDR) were analysed.
|
21068134 |
2011 |
|
rs8099917
|
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Sensitivity analyses suggested the robustness of the results in this meta-analysis.Both IL28B rs12979860 CC and rs8099917 TT genotypes are protective factors for the development of HCC among patients with HBV or HCV infection.
|
31568008 |
2019 |
|
rs8099917
|
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
IL28B (rs12979860 and rs8099917) single nucleotide polymorphisms (SNPs) have been recently found among the Pakistani population associated with response to chronic HCV infection INF-α + ribavirin therapy.
|
26177560 |
2015 |
|
rs8099917
|
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
HCV amino acid (aa) substitutions in non-structural protein 5a, including those in the IFN/RBV resistance-determining region (IRRDR) and the IFN sensitivity-determining region and the core regions, as well as the genetic variation (rs8099917) near the interleukin 28B (IL28B) gene (genotype TT) were analyzed.
|
22441534 |
2012 |
|
rs8099917
|
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
IL28B rs12979860 and rs8099917 single nucleotide polymorphisms are significantly associated with SC of HCV infection.
|
23611115 |
2013 |
|
rs8099917
|
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
The association of rs12979860 and rs8099917 single nucleotide polymorphisms (SNPs) near IL28B with sustained virological response (SVR) in hepatic allograft recipients undergoing treatment with PEGylated interferon (PEG-IFN) plus ribavirin (RBV) for recurrent hepatitis C virus (HCV) infection remains inconclusive.
|
25225180 |
2014 |
|
rs8099917
|
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
In adjusted analyses, low plasma maxi-LVP level was independently associated with spontaneous HCV clearance (≤827 IU/ml; adjusted odds ratio 3.98, 95% CI: 1.02, 15.51, P = 0.047), after adjusting for interferon lambda-3 rs8099917 genotype, estimated duration of HCV infection and total HCV RNA level.
|
27224844 |
2016 |
|
rs8099917
|
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
the Interferon lambda (IFNL) polymorphisms genotypes (rs8099917, rs12979860 and rs12980275) and the presence of mutations in HCV core protein were analyzed in 59 patients with HCC, and also in 50 cirrhotic patients (without HCC).
|
27035616 |
2016 |